Skip to main content
. Author manuscript; available in PMC: 2014 Nov 14.
Published in final edited form as: Leuk Res. 2013 Jul 25;37(11):1440–1444. doi: 10.1016/j.leukres.2013.07.007

Table 2.

Baseline Clinical Characteristics of Patients Who Received Pomalidomide 3.0 mg/day (N = 21)

Characteristic Number (%)/ Median
Age (years) 66 [53–82]
Male 11 (52%)
Diagnosis
 PMF 14 (67%)
 Post-ET MF 4 (19%)
 Post-PV MF 3 (14%)
Splenomegaly 9 (43%)
Hemoglobin, g/dL 9.5 [7.2–11.4]
White Blood Cell Count × 109/L 5.5 [2.0–21.7]
Platelets × 109/L 152 [52–858]
JAK 2 V617 F mutated 12 (57%)
Karyotype
 Diploid 14 (67%)
 Abnormal 5 (24%)
 Indeterminate 2 (9%)
Prior treatment 16 (76%)

Abbreviations: PMF, primary myelofibrosis; Post-ET MF, post essential thrombocythemia myelofibrosis; post-PV MF, post polycythemia vera myelofibrosis.